Skip to main content
. 2022 Sep 12;11(1):572–587. doi: 10.1080/21623945.2022.2098583

Figure 8.

Figure 8.

Schematic diagram shows that ADSC-EVs delayed the progression NAFLD through the delivery of anti-fibrotic miR-223-3p and subsequent E2F1 suppression.